Prevalence and mutational determinants of high tumor mutation burden in breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prevalence and mutational determinants of high tumor mutation burden in breast cancer

Published:2020-03 Issue:3 Volume:31 Page:387-394
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Barroso-Sousa R.,Jain E.,Cohen O.,Kim D.,Buendia-Buendia J.,Winer E.,Lin N.,Tolaney S.M.,Wagle N.

Funder

Breast Cancer Alliance

Susan G. Komen

V Foundation for Cancer Research

National Cancer Institute

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference30 articles.

1. Current landscape of immunotherapy in breast cancer: a review;Adams;JAMA Oncol,2019

2. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer;Schmid;N Engl J Med,2018

3. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting;Matsushita;Nature,2012

4. Expression of tumour-specific antigens underlies cancer immunoediting;DuPage;Nature,2012

5. Mutant MHC class II epitopes drive therapeutic immune responses to cancer;Kreiter;Nature,2015

Cited by 255 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for breast cancer: New strategies to enhance the patient selection and overcome therapeutic resistance;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Identification of lysine lactylation (kla)-related lncRNA signatures using XGBoost to predict prognosis and immune microenvironment in breast cancer patients;Scientific Reports;2024-09-03

3. Exploring the multifaceted role of key lncRNA in glioma: From genetic expression to clinical implications and immunotherapy potential;Heliyon;2024-09

4. Insights into E-Cadherin Impairment in CDH1-Unaltered Invasive Lobular Carcinoma: A Comprehensive Bioinformatic Study;International Journal of Molecular Sciences;2024-08-17

5. Comprehensive Assessment of Immune Phenotype and Its Effects on Survival Outcomes in HER2-Low versus HER2-Zero Breast Cancer;Breast Cancer: Targets and Therapy;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3